Growing up with parenteral nutrition
Paul, the four-legged therapist
The History of Dialysis
’Remain true to your ideals’
Serving patients in Swaziland
Using protons to take on cancer
A little heart at the center of a complex surgery
On duty in disaster zones
More ‘Quality of Life’ in clinics
Ready to help the littlest ones
"I want to help others, so they won’t give up"
From a local pharmacy to a global corporation
Fresenius Kabi’s product portfolio comprises a comprehensive range of I.V. generic drugs, infusion therapies and clinical nutrition products as well as the devices for administering these products. In the field of biosimilars, Fresenius Kabi focuses on autoimmune diseases and oncology. In 2019, the first biosimilar product by Fresenius Kabi was launched. Within transfusion medicine and cell therapies, Fresenius Kabi offers products for collection and processing of blood and cell components.
With its corporate philosophy of "caring for life", the company is committed to putting essential medicines and technologies in the hands of people who help patients and finding the best answers to the challenges they face.
Fresenius Kabi employs over 38,000 people worldwide. In 2018 the company reported sales of more than €6.5 billion. Fresenius Kabi AG is a wholly owned subsidiary of the Fresenius SE & Co. KGaA health care group.
